UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING | OMB APPROVAL | |||
OMB Number: 3235-0058 Expires: April 30, 2009 Estimated average burden hours per response...2.50 | ||||
| SEC FILE NUMBER | ||||
CUSIP NUMBER | ||||
(Check one): oForm 10-K oForm 20-F oForm 11 -K ý Form 10-Q oForm 10-D oForm N-SAR oForm N-CSR | ||||
| For Period Ended: | March 31, 2006 | |||
oTransition Report on Form 10-K oTransition Report on Form 20-F oTransition Report on Form 11-K oTransition Report on Form 10-Q oTransition Report on Form N-SAR | ||||
| For the Transition Period Ended: ___________________________________________ | ||||
Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. | ||||
| If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: | ||||
PART I — REGISTRANT INFORMATION | ||||
| China Biopharmaceuticals Holdings, Inc. | ||||
| Full Name of Registrant | ||||
| Former Name if Applicable | ||||
| Suite 1601, Building A, Jinshan Tower No. 8, Shan Xi Road | ||||
Address of Principal Executive Office (Street and Number) | ||||
| Nanjing, Jiangsu Province, People's Republic of China | ||||
City, State and Zip Code PART II — RULES 12b-25(b) AND (c) If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) | ||||
| x | (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense | |||
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution reporton Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and | ||||
(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. | ||||
PART III — NARRATIVE The registrant is in the review process with its auditors. The registrant anticipates filing within the five-day extension period. | ||||
| SEC 1344 (03-05) | Persons who are to respond to the collection of information contained in this form required to respond unless the form displays a currently valid OMB control number. |
(Attach extra Sheets if Needed) PART IV — OTHER INFORMATION (1) Name and telephone number of person to contact in regard to this notification | ||||||
| Chris Peng Mao | 011-86 | 25-8320-5758 | ||||
| (Name) | (Area Code) | (Telephone Number) | ||||
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s). Yes x No o | ||||||
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ? Yes x Noo If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. The Registrant's revenue increased significantly in the three months ended March 31, 2006 as compared to the corresponding period for year 2005. Such increases are mainly due to the acquisitions made by the Registrant in year 2005 as disclosed in its various reports filed with the Securities and Exchange Commission by the Registrant. | ||||||
China Biopharmaceutical Holdings, Inc. | ||||||
| (Name of Registrant as Specified in Charter) | ||||||
| has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. | ||||||
| ___________________________ | ___________________________ | |||||
